Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Laparoscopic cholecystectomy is the treatment of choice for cholecystitis

Better outcomes can be achieved using laparoscopic cholecystectomy compared to open cholecystectomy when treating acute and chronic cholecystitis, finds a new study of 43,433 patients.

News image

fiogf49gjkf04

Laparoscopic cholecystectomy (LC) has become a popular alternative to open cholecystectomy (OC). However, previous studies comparing outcomes in LC and OC have only used small selected cohorts of patients, and did not control for comorbid conditions that might affect outcome.

A report from scientists at the University of North Carolina at Chapel Hill, USA, has now attempted to rectify this.

Writing in the latest issue of the American Journal of Gastroenterology, the research group carried out their study on a large unselected cohort of patients, with the aims of characterizing the morbidity, mortality, and costs of LC and OC.

The group used the population-based North Carolina Discharge Abstract Database for January 1, 1991, to September 30, 1994 (n = 850,000) to identify patients undergoing LC and OC.

This produced a cohort of 43,433 patients (19,662 LC and 23,771 OC).

Indications for surgery, complications, and the type of preoperative biliary imaging used were then identified for all subjects within the cohort.

Open patients - 3 times more likely to die than laparoscopy patients
American Journal of Gastroenterology

In addition, the length of stay, hospital charges, complications, morbidity, and mortality between LC and OC patients were compared.

To account for variations in outcomes from differences in age and comorbidity between the LC and OC groups, researchers applied the age-adjusted Charlson Comorbidity Index in regression analyses quantifying the association between type of surgery and outcome.

The mean-age adjusted Charlson Comorbidity Index score was found to be slightly higher for the OC group compared to the LC group.

The OC patients had longer hospitalizations, generated more charges and also required home care more frequently.

The crude risk ratio, comparing risk of death in OC to LC was 5.0 (95% CI = 3.9-6.5).

After controlling for age, comorbidity, and sex, the likelihood of dying in the OC group was still 3.3 times (95% CI = 1.4-7.3) greater than in the LC group.

In the LC group, the number of patients with acute cholecystitis rose over the study period, whereas the number of patients with chronic cholecystitis declined.

In the OC group however, the number of patients with both chronic and acute cholecystitis declined.

The use of intra-operative cholangiography was greater in the OC group, but declined in both groups over the study period.

The use of ERCP was greater in the LC group and increased in both groups over time.

Summarizing the research group's findings, Dr S.L. Zacks, said, "The introduction of LC has resulted in a change in the management of cholecystitis."

"Despite a higher proportion of patients with acute cholecystitis, our study found the risk of dying was significantly less in LC than in OC patients, even after controlling for age and comorbidity."

He concluded, "Based on lower costs and better outcomes, LC seems to be the treatment of choice for acute and chronic cholecystitis."

Am J Gastroenterol 2002; 97(2): 334-40
12 March 2002

Go to top of page Email this page Email this page to a colleague

 23 February 2018 
Patients on antithrombotic agents undergoing emergency and elective endoscopy
 23 February 2018 
Heavy metals on a gluten-free diet
 23 February 2018 
MRI and NAFLD
 22 February 2018 
Outcomes with Crohn’s after infliximab withdrawal
 22 February 2018 
Elderly onset of IBD

 22 February 2018 
Autophagy enhancers
 21 February 2018 
Management of hemorrhoids in the USA
 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 20 February 2018 
Complications and surveillance colonoscopies
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us